• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Aehr Test Systems (AEHR) Is Up 11.6% After AI-Focused Backlog Grows Despite 2026 Net Loss

    Simply Wall St·07/18/2026 07:27:26
    Listen to the news
    • Aehr Test Systems reported past fourth-quarter 2026 results with sales of US$18.84 million and net income of US$1.39 million, while full-year 2026 sales fell to US$50.00 million alongside a net loss of US$7.13 million.
    • Management highlighted a sharp shift in revenue mix toward AI processors, silicon photonics, and power semiconductors, backed by record bookings and an effective backlog above US$80.00 million.
    • We’ll now examine how this AI-driven revenue guidance and expanding backlog shape Aehr Test Systems’ investment narrative for investors.

    We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    What Is Aehr Test Systems' Investment Narrative?

    To own Aehr Test Systems today, you need to believe its wafer-level burn-in tools can carve out a durable niche in AI processors, silicon photonics, and power semiconductors, despite recent earnings volatility and a still-unprofitable year. The latest quarter helps that story: Q4 swung back to profit, bookings hit a record US$60.70 million, and management is guiding to US$130–150 million in fiscal 2027 revenue with an effective backlog above US$80 million. That materially reshapes the near-term catalyst picture, shifting focus from past dependence on electric-vehicle silicon carbide to AI-driven orders and execution against this upgraded outlook. At the same time, the sharp share price move, rich price-to-book multiple, index removal, and insider selling keep valuation risk very much in play, especially if AI orders or customer ramps slip.

    However, the rich valuation and recent insider selling are things investors should not ignore. Our expertly prepared valuation report on Aehr Test Systems implies its share price may be too high.

    Exploring Other Perspectives

    AEHR 1-Year Stock Price Chart
    AEHR 1-Year Stock Price Chart
    Four fair value estimates from the Simply Wall St Community span roughly US$16 to US$115, showing wide disagreement. Set that against Aehr’s AI-fueled guidance and execution risk, and you can see why it pays to weigh several viewpoints before deciding how this stock might fit your portfolio.

    Explore 4 other fair value estimates on Aehr Test Systems - why the stock might be worth as much as 42% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Seeking Other Investments?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.